• Facebook Social Icon
  • Twitter Social Icon
  • Instagram Social Icon

Osteoarthritis Pain of the Knee


Clinics: Manchester

Therapy Area: Osteoarthritis

Gender and Age: Males & Females aged 18-80


MAC Clinical Research is currently conducting a clinical research study into a potential new medication for the treatment of Osteoarthritis of the knee.

Osteoarthritis is a condition that causes joints to become painful and stiff. It's the most common type of arthritis in the UK. Over 8 million people in the UK are affected by joint pain caused by this condition. It usually affects the, hips, knees, hands, feet and spine.


Although there are currently treatments available, there is a great medical need for medications with improved, more sustained effects on pain and stiffness and lesser side effects. Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids provide some relief from mild to moderate chronic pain. However, only half of patients treated will achieve enough pain relief. These drugs also cause many side effects.


MAC Clinical Research is assessing a treatment known as MEDI7352. This is a novel molecule that can potentially assist with the reversal of pain in Arthritis.

The main objective of this study is to assess the safety and effectiveness of MEDI7352 in participants with painful Osteoarthritis of the knee.

Reimbursement: £2,800


Key Inclusion Criteria

  • Participants must be ages between 18 and 80 years old.

  • Insufficient response to current or past pain relief.

  • Current diagnosis of Osteoarthritis in one or both knees

  • One knee must be designated as the target joint and must exceed the pain experienced in other joints and any other medical conditions.

Key Exclusion Criteria

  • Requires treatment with another biologic therapeutic agent.

  • History of gout.

  • Significant cardiovascular disease.

  • Diagnosis of significant neuropathy

  • A diagnosis of immunological conditions such as Rheumatoid Arthritis, traumatic arthritis (within past year) or seronegative spondyloarthropathy.

Other eligibility criteria will apply. Please contact MAC for more information.